Eli Lilly And Co (LLY) is Private Capital Advisors Inc.’s Largest Position

Private Capital Advisors Inc. raised its holdings in Eli Lilly And Co (NYSE:LLY) by 0.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 388,539 shares of the company’s stock after acquiring an additional 2,990 shares during the quarter. Eli Lilly And Co comprises approximately 11.3% of Private Capital Advisors Inc.’s holdings, making the stock its largest position. Private Capital Advisors Inc.’s holdings in Eli Lilly And Co were worth $33,236,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Integrated Wealth Concepts LLC acquired a new stake in shares of Eli Lilly And Co in the second quarter worth $103,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in shares of Eli Lilly And Co in the second quarter worth $114,000. Legacy Advisors LLC lifted its stake in shares of Eli Lilly And Co by 118.0% in the second quarter. Legacy Advisors LLC now owns 1,354 shares of the company’s stock worth $116,000 after buying an additional 733 shares during the last quarter. Fort L.P. acquired a new stake in shares of Eli Lilly And Co in the second quarter worth $121,000. Finally, Financial Management Professionals Inc. acquired a new stake in shares of Eli Lilly And Co in the second quarter worth $128,000. Hedge funds and other institutional investors own 76.56% of the company’s stock.

A number of brokerages have recently weighed in on LLY. Zacks Investment Research upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $129.00 price objective for the company in a research note on Tuesday. Guggenheim began coverage on shares of Eli Lilly And Co in a research note on Monday, October 8th. They issued a “buy” rating for the company. ValuEngine upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating in a research note on Monday, October 8th. JPMorgan Chase & Co. set a $123.00 price objective on shares of Eli Lilly And Co and gave the stock a “buy” rating in a research note on Friday, October 5th. Finally, BMO Capital Markets upgraded shares of Eli Lilly And Co from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $107.00 to $130.00 in a research note on Thursday, October 4th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $107.88.

Shares of LLY stock opened at $110.48 on Friday. Eli Lilly And Co has a 1 year low of $73.69 and a 1 year high of $116.61. The firm has a market cap of $115.25 billion, a P/E ratio of 25.81, a P/E/G ratio of 1.88 and a beta of 0.29. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.09 and a current ratio of 1.40.

Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Tuesday, July 24th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.30 by $0.20. Eli Lilly And Co had a negative net margin of 0.60% and a positive return on equity of 39.84%. The business had revenue of $6.36 billion for the quarter, compared to analyst estimates of $6.05 billion. During the same quarter in the previous year, the firm posted $1.11 earnings per share. Eli Lilly And Co’s revenue was up 9.1% compared to the same quarter last year. Analysts predict that Eli Lilly And Co will post 5.47 EPS for the current year.

In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 14,632 shares of the business’s stock in a transaction on Monday, October 8th. The shares were sold at an average price of $115.91, for a total value of $1,695,995.12. Following the sale, the insider now owns 119,191,172 shares of the company’s stock, valued at approximately $13,815,448,746.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Eli & Co Lilly sold 4,531 shares of the business’s stock in a transaction on Monday, August 13th. The shares were sold at an average price of $14.33, for a total transaction of $64,929.23. Following the completion of the sale, the insider now directly owns 3,934,137 shares in the company, valued at approximately $56,376,183.21. The disclosure for this sale can be found here. Insiders have sold 1,785,575 shares of company stock worth $180,166,130 in the last ninety days. 0.11% of the stock is currently owned by insiders.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: What is a Call Option?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply